Neko Health and Neuralink Trial Candidates Screening via Body-Scan Data

Neko Health and Neuralink reportedly collaborate on a “trial candidates screening” survey using Neko’s full-body scan data, after a social media announcement. The aim is to speed up eligibility checks for Neuralink’s brain-computer interface clinical trials. Neko Health provides preventive monitoring through one-hour full-body scans using proprietary sensors. Each session generates millions of data points covering skin health, cardiovascular function, and other biological metrics. Neko’s scan service is priced at $499 in the US. The company raised $700 million in its Series C round (closed July 15, 2026) and plans to open its first US clinic in New York City on September 24, 2026. For Neuralink, the screening challenge is high-stakes. Its PRIME Study focuses on patients with quadriplegia from spinal cord injuries or ALS, where eligibility criteria are narrow and mistakes could be severe. Under the reported arrangement, consented Neko Health users would opt in to allow their body-scan data to be used for trial pre-screening. If feasible, a single comprehensive health snapshot could flag disqualifying conditions earlier in the pipeline. Key uncertainties remain. The consent mechanism is unclear, and the medical usefulness of Neko Health’s scan data for Neuralink’s specific neurological requirements is not fully established. Neko’s scans emphasize skin and cardiovascular metrics, while PRIME Study eligibility requires specialized neurological evaluation. As of Aug. 23, 2026, no formal partnership has been confirmed through official channels; the report is based on social media. Investors should treat this as unverified until a primary-source announcement is made.